Letteratura scientifica selezionata sul tema "Métastase cérébrale"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Métastase cérébrale".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Métastase cérébrale":
Herrak, L., N. Jahnaoui, S. Hammi, N. El Asri, L. Achachi, M. El Ftouh, H. Mansouri e M. T. El Fassy Fihry. "Métastase cérébrale d’une tumeur bronchopulmonaire « fantôme »". Revue de Pneumologie Clinique 68, n. 4 (agosto 2012): 243–48. http://dx.doi.org/10.1016/j.pneumo.2011.09.007.
Ahle, Guido, Claude Gaultier, Ionela Manoila, Monia Cardarelli, Jérôme Guison, David Atlani e Jimmy Voirin. "S’agit-il d’une métastase cérébrale ? Qui et quand biopsier ?" Revue Neurologique 172 (aprile 2016): A150. http://dx.doi.org/10.1016/j.neurol.2016.01.355.
Semjen, F., P. Caillaud, M. Mehsen, G. Boulard e P. Maurette. "Hémorragie intraventriculaire incoercible révélatrice d’une métastase cérébrale d’un mélanome malin". Annales Françaises d'Anesthésie et de Réanimation 20, n. 5 (maggio 2001): 488–89. http://dx.doi.org/10.1016/s0750-7658(01)00396-3.
Kadem, M., C. Bourquard, S. Lassandre, R. Duthel, N. Vergely e B. Estour. "P227 Révélation atypique d’un microcarcinome thyroïdien papillaire par une métastase cérébrale". Annales d'Endocrinologie 66, n. 5 (ottobre 2005): 491. http://dx.doi.org/10.1016/s0003-4266(05)82068-2.
Vulpoi, C., I. Poeata, M. Grigoras, L. Leustean, A. Chriac, M. C. Ungureanu, C. Bogdanici, D. Boisteanu e E. Zbranca. "P1-108 - Diabète insipide d’apparition brutale – premier signe d’une métastase cérébrale". Annales d'Endocrinologie 67, n. 5 (ottobre 2006): 443. http://dx.doi.org/10.1016/s0003-4266(06)72761-5.
Bonnet, D., J. Eskandari, J. L. Barat, J. M. Peloni, D. Verrot, J. Miltgen, E. Saguy, M. Bregigeon e C. Brosset. "Métastase(s) cérébrale(s) d’un cancer bronchique non à petites cellules". Revue de Pneumologie Clinique 60, n. 3 (giugno 2004): 180–81. http://dx.doi.org/10.1016/s0761-8417(04)72095-7.
Vendrely, V., L. Prié, A. Benyoucef, A. Chemin e G. Kantor. "Radiochirurgie de métastase cérébrale unique sans irradiation cérébrale totale associée. Résultats d'une série consécutive de 12 cas". Cancer/Radiothérapie 2, n. 4 (luglio 1998): 375–80. http://dx.doi.org/10.1016/s1278-3218(98)80349-1.
Marec-Bérard, P., F. Khelfaoui, D. Frappaz, C. Carrie, J. M. Zucker, M. Brunat-Mentigny e E. Bouffet. "Rémission prolongée chez un enfant présentant une métastase cérébrale tardive de rétinoblastome]". Archives de Pédiatrie 3, n. 10 (ottobre 1996): 1001–5. http://dx.doi.org/10.1016/0929-693x(96)81723-4.
Chraïbi, M., M. Benzagmout, H. El Fatemi, M. Boubou, K. Znati, S. Bennis, K. Chakour, S. Tizniti e A. Amarti. "Métastase cérébrale à partir d’un carcinome du col utérin: à propos d’un cas". Oncologie 12, S1 (12 novembre 2009): 62–65. http://dx.doi.org/10.1007/s10269-008-0956-6.
Patsouris, A., P. Augereau, J. Y. Tanguy, O. Morel, P. Menei, A. Rousseau e A. Paumier. "Diagnostic différentiel entre récidive tumorale et radionécrose après radiothérapie stéréotaxique d’une métastase cérébrale". Cancer/Radiothérapie 18, n. 2 (marzo 2014): 142–46. http://dx.doi.org/10.1016/j.canrad.2013.10.013.
Tesi sul tema "Métastase cérébrale":
Cicero, Julien. "TrkA dans les métastases cérébrales des cancers du sein triple négatifs". Electronic Thesis or Diss., Université de Lille (2022-....), 2023. http://www.theses.fr/2023ULILS031.
Nearly 90% of deaths in breast cancer patients are due to metastasis. Triple-negative(TN) breast cancer is characterized by its aggressive nature and high propensity to metastasize. Among the various sites of metastasis, the development of brain metastasis is associated with the worst prognosis, with a greater impact on patients'quality of life. The mechanisms underlying the progression of brain metastases in triplenegativebreast cancer are incompletely understood. To address this gap, we have used several experimental models to study the behavior of breast cancer cells during the process of dissemination to the brain. These models include an in vitro human blood-brain barrier (BBB) model, in vitro 3D organotypic extracellular matrix, ex vivo co-cultures of mouse brain slices, and in vivo xenograft experiments. By recapitulating the final key steps of brain metastasis in these models, we sought to better understand the underlying molecular mechanisms. In this work, we demonstrate the involvement of TrkA and its co-receptors (e.g. EphA2) in the development of brain metastases. First, we identified the TrkA/EphA2 receptor complex as a mediator of proNGF-induced BBB transmigration. Furthermore, our results showed that combined inhibition of TrkA and EphA2 significantly reduced brain metastasis in a preclinical breast cancer model. These results challenge the current understanding of the mechanisms of brain metastasis and highlight the role of proNGF as a key factor in the brain tropism of metastatic TN breast cancer
Tomasini, Pascale. "Établissement d'un profil génomique spécifique des métastases cérébrales des adénocarcinomes bronchiques". Thesis, Aix-Marseille, 2019. http://www.theses.fr/2019AIXM0692.
Lung cancer is the leading cause of cancer-related deaths, partly because it is the first cause of brain metastases (BM). A better knowledge of non-small cell lung cancer (NSCLC) molecular biology and the development of targeted therapies have improved patients’ outcomes. However, the intracranial efficacy of these new treatments is inconstant. The objective of this work was a better knowledge of BM biology in lung adenocarcinoma and a better knowledge of genomic heterogeneity between BM and PT to guide patients’ treatment strategy.We showed that intracranial efficacy of immunotherapy was inconstant and that BM incidence and recurrence after local treatment was associated with mutation profile. We then compared whole exome sequencing of paired frozen samples from PT and BM of patients with NSCLC and identified 13 genes with recurrent mutations in BM never mutated in PT samples. We then analyzed a prospective cohort of patients with CBNPC and resected BM. In these BM, the number of mutations was high, including 2 genes among the 13 genes identified. Moreover, CSF ctDNA was representative of BM mutation status.This work highlights the importance of tumor heterogeneity between BM, PT and ctDNA. Whereas it is difficult to establish a specific signature of BM because of the poor number of samples available and the difficulty to have paired PT/BM samples for each patient, CSF ctDNA study may be a way to assess BM biology. We plan to study brain microenvironment and use new approaches such as mathematical modeling for a better understanding of BM biology
Varga, Béla. "Rôle de la nanobiomécanique dans la formation de métastases cérébrales et la sclérose latérale amyotrophique". Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTS085/document.
Nano-biomechanics is an emerging field of science that opened a new horizon in scientific research by generating significant contribution in the study of human diseases. In this work, atomic force microscopy-based nanomechanical methods were directly applied in order to elucidate important questions related to brain metastasis formation and amyotrophic lateral sclerosis (ALS). Better understanding of the underlying pathogenic processes of these life-threatening diseases is fundamental for the advancement of early diagnostics and improved therapeutics.A malignant tumor cell, in order to spread and form metastasis, has to vary and continuously adapt its adhesive and elastic properties. Here, we combined force mapping with single cell force spectroscopy (SCFS) in order to gain direct insight into the surface “screening” process of tumor cells during their extravasation into the brain parenchyma. Intercellular adhesive forces and works, as well as elastic properties were spatially mapped showing that adhesive properties are only slightly dependent on elastic characteristics, and highlighting the importance of long range tether-like linkages for successful adhesions.In order to examine how the metastatic potential relates to tumor cell’s autonomous and inter-cellular nanomechanical properties, comparative SCFS measurements were performed between three melanoma cell types (WM35, A2058 and A375), showing altered invasive characteristics, and blood vessel lining endothelials. Our results indicate low relative elasticity, high maximal adhesion and high number of individual linkages, as the key properties of highly metastatic melanoma cells. This enables us to suggest the following ordering of tumor cells from lower to higher metastatic potential: WM35, A2058 and A375.The pathogenesis of ALS is multifactorial, being characterized by the presence of inflammatory processes as well. In our results significant differences have been observed, by comparing the adhesion of CD8+ cytotoxic T cells isolated from wild-type as well as SOD1G93A mutant mice against wild-type motor neurons. Mutant mice derived T cells show enhanced adhesion strength, compared to the healthy mice derived ones. Moreover, we observe a significant reduction of T cell - motoneuron interactions after blocking the specific recognition bindings between pMHC-I and TCR. These results corroborate the contribution of cytotoxic T cells in the development of ALS, as an active player in neurodegeneration.Investigating primary myoblasts allow deciphering molecular processes involved in muscle development, aging and repair. Therefore, in our study high resolution nanomechanical mapping was performed on single elongated myoblasts and multinuclear myotubes, isolated from an ALS mouse model, to reveal elasticity features during early differentiation stage into myotubes. We have found that projections of the elongated myoblasts show significantly increased elastic modulus values compared to their cell body. Regarding myotubes, differences have been observed between the elasticity of a thin and thick population of wild-type myotubes, indicating the different maturity of the two populations. However, in SOD1 mutant, the observed increase in the elastic modulus of the thin population suggests an enhanced autonomous hardening of ALS derived myotubes.In summary, our cellular-level mechanical studies deciphered various aspects of two different life-threatening pathologies resulting in novel discoveries about their fundamental processes. This work highlights the high impact and the important role of AFM-based nanomechanical methods in providing valuable knowledge about disease pathophysiology, development, diagnostics and progression that could contribute to the evolvement of future therapies
Gomez, Adeline. "Approche psychologique de la qualité de vie de patients atteints de métastases cérébrales : temps, émotion et cognition". Thesis, Montpellier 3, 2017. http://www.theses.fr/2017MON30092/document.
Little is known about the psychological determinants of quality of life in brain metastases patients treated with neurosurgical techniques, in particular the contribution of cognitive and emotional functioning. Authors encourage the consideration of temporality in order to better understand the concept of quality of life. Zimbardo and his collaborators developed a psychological time theory that links quality of life and depression, called the "time perspective". The thesis aims to confirm the predictive role of cognitive functioning in the quality of life of patients treated surgically for metastatic cerebral tumors and to better understand the relationships between time perspective, depression and quality of life. A first study compared the sociocognitive profile in inter-subjects (patients versus controls) and in intra-subjects (before neurosurgical treatment versus after), and explored determinants of quality of life (ie, cognitive functioning, depressive symptomatology and time perspective). The main results are that patients have a global cognitive dysfunction that negatively impairs their functional autonomy and that a depressive symptomatology, even minimal, is an important predictor of their overall quality of life. Patients are more oriented towards the "present-fatalistic " than the controls, and the "past" dimensions of their time perspective are related to their quality of life, notably through their influence on the emotional state. A second study examined the relationship between the "past-negative" dimension of the time perspective in particular, depression and quality of life in a group of patients. The results suggest that the depressive symptomatology of patients mediate the effects of the "past negative" dimension on their quality of life. A third study explored, through a case study, the dynamics of the time perspective profile, depressive symptomatology, "uncertainty towards the future" and quality of life during medical follow-up. The main result of this study is that the dynamics of the two "present" dimensions evolve jointly with the future uncertainty. The thesis encourages the implementation of interventional studies to evaluate the effectiveness of psychological interventions centered on the time perspective in brain metastases patients
Boussion, Véronique. "Intérêt de la tomodensitométrie dans le bilan d' extension des cancers bronchiques primitfs". Clermont-Ferrand 1, 1987. http://www.theses.fr/1987CLF11018.
Verry, Camille. "Traitement des métastases cérébrales par radiothérapie et nanoparticule de gadolinium : du modèle pré clinique à l'utilisation chez l'homme Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase 1 study protocol First in man injection of gadolinium-chelated based nanoparticle (AGuIX®) as theranostic agent for treatment of multiple brain metastases by adiotherapy: a case report". Thesis, Université Grenoble Alpes (ComUE), 2018. http://www.theses.fr/2018GREAS029.
The occurrence of multiple brain metastases is a critical evolution of many cancers with a major impact on overall survival. A new gadolinium-based nanoparticle, AGuIX®, has recently demonstrated its efficacy as a radiosensitizer and MRI contrast agent in several preclinical studies. The objective of this thesis is to establish a proof of concept on an animal model and then to perform the first administration of this new drug in humans in a phase 1 trial. The first part of this work consisted of a 6 MeV irradiation after AGuIX® injection of a Fisher rat model carrying 9L cerebral gliomas assessed by MRI. A favorable distribution of nanoparticles was observed by EPR effect (Enhanced Permeability and Retention) with a concentration of gadolinium into the tumor 20 times higher than in healthy brain. The radiosensitizing effect was demonstrated with a significant decrease in tumor size (p=0.02) for the irradiated group with AGuIX® injection. These results, combined with the favorable safety profile in animal models, motivated the transfer of this new drug to humans in a Phase 1 study named NANO-RAD (EudraCT2015-004259-30; NCT02820454). This is a monocentric, open-label study evaluating the feasibility and safety of AGuIX® combined with whole brain radiation therapy (30 Gy, 10 Fr of 3 Gy) for patients with multiple brain metastases. The main objective is to determine the maximum tolerated dose of nanoparticles with a dose escalation scheme by steps of 3 patients at 15, 30, 50, 75 and 100 mg/kg. Secondary objectives are the pharmacokinetics, distribution of AGuIX® by MRI, intracranial progression-free survival and overall survival. The first human administration was performed at Grenoble University Hospital on 18 July 2016 and the last patient (n=15) was included on 06 February 2018. All metastases, whatever the histological type (lung, melanoma, breast) had a uptake of AGuIX® whose concentration in the tumor was proportional to the injected dose. The average blood half-life is 1h09 (± 26 min). Tolerance to the treatment was good with a dose escalation up to 100 mg/kg, which became the dose selected for further clinical trials. Of the 14 evaluable patients, 12 had a clinical benefit of treatment with a decrease in tumor volume. These preliminary results are promising in terms of safety, distribution and efficacy and should be confirmed by the randomized multicenter Phase 2 study planned for the end of 2018
La, Folie Trévor. "Myxome cardiaque et manifestations neurologiques : étude rétrospective sur 10 observations". Bordeaux 2, 1998. http://www.theses.fr/1998BOR2M128.
Guedj, Jérôme. "Cancers bronchiques non à petites cellules et métastases cérébrales : étude prospective par modèles de COX des déterminants du pronostic chez 614 malades". Montpellier 1, 1999. http://www.theses.fr/1999MON11017.
Duhalde, Philippe. "Place de la tomodensitométrie cérébrale dans le bilan préthérapeutique et la surveillance du cancer bronchique non à petites cellules". Bordeaux 2, 1995. http://www.theses.fr/1995BOR2M173.
Drolez, Aurore. "Métastases cérébrales des cellules du cancer du sein : étude in vitro des mécanismes responsables du passage au travers de la Barrière Hémato Encéphalique". Thesis, Artois, 2016. http://www.theses.fr/2016ARTO0404/document.
Worldwide, one in nine women will suffer from breast cancer and about a third of them will develop distant metastases, mainly in the lung, the bones and the brain. Brain metastases are associated with poor prognosis and reduced overall survival because most of the available anticancer agents proved to be ineffective because of their failure to cross the Blood-Brain Barrier (BBB) to target brain metastases. Hence, prevent cancer cells to cross the BBB can be considered as one of therapeutic strategies to reduce brain metastases development. However, this includes the prior identification of still unknown molecular mechanisms involved during interactions between cancer cells and BBB endothelial cells. It is in this context that this thesis work has been drawn up. It shows that the relevance of results obtained from in vitro studies heavily depends on the quality of the chosen BBB model. The use of several in vitro models demonstrates that only the one generated from human stem cells provides results in accordance with clinical data. This model also enables study of specific mechanisms responsible for interactions between cancer cells and BBB endothelial cells during brain metastases formation
Capitoli di libri sul tema "Métastase cérébrale":
Lartigau, E., e Y. Belkacémi. "Irradiation des métastases cérébrales des tumeurs du sein". In Cancer du sein avancé, 257–58. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-72615-6_28.
Paquis, P., e F. Fauchon. "Stratégie de prise en charge des métastases cérébrales du cancer du sein". In Cancer du sein en situation métastatique, 111–17. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_12.
Vieillot, S., C. Bourgier e D. Azria. "Techniques innovantes en radiothérapie, description et application aux cancers du sein métastatique (hors métastases cérébrales)". In Cancer du sein en situation métastatique, 59–68. Paris: Springer Paris, 2010. http://dx.doi.org/10.1007/978-2-8178-0076-9_7.